It's the latest stride by Nvidia and the pharmaceutical industry to harness AI to try to reduce costs and shorten the time it ...

The draft guidance, which is touted as a way to reduce the cost and time-associated burden of biosimilar development, has ...

There are three obstacles to faster development and deployment of non-addictive pain treatments. They are the business ...

CHENNAI: The researchers from Indian Institute of Technology Madras and The Ohio State University, US, have developed a breakthrough Artificial Intelligence (AI ...

The US Food and Drug Administration will take steps to streamline the process to develop generic versions of complex biological drugs, the agency announced Wednesday. The changes are meant to ...

POTOMAC, MARYLAND / ACCESS Newswire / / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a ...

So far, the USFDA has approved 76 biosimilars but the market share of these remains below 20% with only 10% of the biologics ...

The United States has said it will speed up approval for some generic drugs. The development comes weeks after it was ...

IIT Madras announces the 'PURE' AI framework, promising significant reductions in drug development timelines. Developed with Ohio State University, PURE uses reinforcement learning to optimize ...

FDA announces major reforms to streamline biosimilar approvals, potentially saving Americans billions on prescription drug costs by removing extra clinical trial requirements.

Researchers from IIT Madras and Ohio State University have developed an AI framework called PURE that can quickly generate drug-like molecules suitable for real-world synthesis. This innovation aims ...